MedTrace Logo

Infant RSV Immunity Study

NCT07653347 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-06-17

No results posted yet for this study

Summary

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.

Conditions

  • Respiratory Synctial Virus
  • Asthma Childhood

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Eligibility

Max Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2027-06-01
Completion
2029-12-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07653347 on ClinicalTrials.gov